



Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/662,044
				Filing Date	9/11/2003
				First Named Inventor	Subhra Chakrabarti
				Art Unit	1642
				Examiner Name	Catherine Joyce
Sheet	1	Of	1	Attorney Docket Number	31302-702.201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	1.	APANTAKU, L.M., "Breast cancer diagnosis and screening," American Family Physician August 1, 2000,; 62(3):596-602, 605-6. (Electronic version downloaded from http://www.healthlibrary.com/doctors2/breastcancer2.html)	
	2.	BUSKENS, C. et al., "Adenocarcinomas of the Gastro-Esophagal Junction: A Comparative Study of the Gastric Cardia and the Esophagus with Respect to Cyclooxygenase-2 Expression," Digestive Disease Week Abstracts and Itinerary Planner, Vol. 2003, abstract No. 850, 2003, e-file	
	3.	COTTERCHIO, M. et al., "Ontario Familial Colon Cancer Registry: Methods and First-year Response Rates," Chronic Diseases in Canada Vol. 21, No.2, 2000 (electronic version downloaded from http://www.phac-aspc.gc.ca/publicat/edc-mcc/21-2/f_e.html)	
	4.	GURA, T., "Systems for Identifying New Drugs Are Often Faulty," Science Vol. 278:1041-1042, 7 November 1997	
	5.	MARTIN, A. and WEBER, B.L., "Genetic and Hormonal Risk Factors in Breast Cancer," J. of the National Cancer Inst., Vol. 92, No. 14, July 19, 2000	
	6.	WHITE, C.A., et al., "Antibody-Targeted Immunotherapy for Treatment of Malignancy," Annu. Rev. Med. 2001, 52:125-45	
	7.	October 2005, "Temporary protocol of treatment: Trastuzumab (Herceptin®) in adjuvant conditions," Institut National de Cancer and Agence francaise de securite sanitaire des produits de sante, www.e-cancer.fr/medias/pttdefeng2710.pdf	

Examiner Signature		Date Considered	9/3/04
--------------------	---	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.